Cytochrome P450 2C19 (abbreviated CYP2C19), a member of the cytochrome P450 mixed-function oxidase system, is involved in the metabolism of xenobiotics in the body. It is involved in the metabolism of several important groups of drugs including many proton pump inhibitors and antiepileptics.
Genetic polymorphism exists for CYP2C19 expression, with approximately 3–5% of Caucasian and 15–20% of Asian populations being poor metabolisers with no CYP2C19 function.
| Selected inducers, inhibitors and substrates of CYP2C191 | |
| Type | Agent |
| inducers | carbamazepine, norethindrone, prednisone, rifampicin |
| inhibitors | chloramphenicol, cimetidine, fluoxetine, fluvoxamine, indomethacin, ketoconazole, lansoprazole, modafinil, omeprazole, oxcarbazepine, probenecid, ticlopidine, topiramate |
| substrates | amitriptyline, antiepileptics (incl. diazepam, phenytoin, phenobarbital), citalopram, clomipramine, cyclophosphamide, imipramine, indomethacin, moclobemide, nelfinavir, primidone, progesterone, proguanil, propranolol, proton pump inhibitors (lansoprazole, omeprazole, pantoprazole, rabeprazole, etc), teniposide, warfarin |
| Notes: | |